In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
- TRADE NAME: Coartem (Novartis)
- INDICATIONS: Acute, uncomplicated malaria infections due to Plasmodium falciparum in patients of 5kg bodyweight and above
- CLASS: Antimalarial
- HALF-LIFE: ~2 hours (artemether); 3–6 days (lumefantrine)
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Amiodarone, Amitriptyline, Amoxapine, Antimalarials, Antiretrovirals, Arsenic, Astemizole, Atazanavir, Atovaquone/Proguanil, Azithromycin, Carbamazepine, Ciprofloxacin, Citalopram, Clomipramine, Conivaptan, CYP2D6 substrates, CYP3A4 inducers, inhibitors or substrates, Darunavir, Dasatinib, Degarelix, Delavirdine, Disopyramide, Dolasetron, Duloxetine, Flecainide, Halofantrine, Hormonal contraceptives, Imipramine, Indinavir, Itraconazole, Lapatinib, Levofloxacin, Levomepromazine, Lopinavir, Mefloquine, Moxifloxacin, Nelfinavir, Norfloxacin, Ofloxacin, Paroxetine Hydrochloride, Pazopanib, Phenytoin, Pimozide, Procainamide, Quinidine, Quinine, Rifampin, Risperidone, Sotalol, St John's Wort, Telavancin, Telithromycin, Terfenadine, Tipranavir, Venlafaxine, Voriconazole, Vorinostat, Ziprasidone, Zuclopenthixol
- See adverse reactions attributed to class:
Artemether/Lumefantrine tablets should not be used to treat severe malaria or to prevent malaria.
Please login to view the rest of this drug profile.
Page last updated 02/16/2024
